Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now later-stage tilt small index

Shock: later-stage trial registry

7 of 10 indexed Shock trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Shock: 10 US clinical trials tracked, 7 recruiting.

Shock is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 2 of these trials.

Enrollment posture brief

Registry condition shock

OPEN 7 | RECR 70% | LATE 4 | EARLY 0 | RANK #1724 | SPON 2

Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)

Acute Leukemia of Ambiguous 80%Shock (this)70%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Shock

Shock lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Shock on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Shock is recruiting above its size-band peers.

    7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Shock research.

    University of Pennsylvania accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Shock enrolment sits around 160 participants.

    Median target enrolment is 160 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Shock splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 44

Phase Distribution

PhaseTrial count
Phase 4 4

Named interventions

Most-linked intervention names on Shock records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

ICD/ Crt-d Device
1 trials
Passive Leg Raise (PLR) Procedure
1 trials
Levalbuterol Drug
1 trials
Albuterol Drug
1 trials
Backup Pacing Rate Change Device
1 trials
Angiotensin II and hydrocortisone sodium succinate Drug
1 trials
Phenylephrine Drug
1 trials
Central venous catheter insertion Procedure
1 trials

US sites by state

Facility locations filed on Shock trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
New York 2 trials
Texas 1 trials
Tennessee 1 trials
Nevada 1 trials
Michigan 1 trials
Illinois 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Shock page

10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Shock condition card totals 10 registered trials; most-linked intervention ICD/ Crt-d; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.